Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Avacopan

- PMLiVE

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos

- PMLiVE

Amgen to acquire ChemoCentryx in $3.7bn cash deal

The agreement includes the acquisition of ChemoCentryx’s autoimmune disease treatment Tavneos

- PMLiVE

ChemoCentryx surges on phase 3 vasculitis study

Shares in the US biotech rose 227% after announcing trial results

- PMLiVE

GSK hands back rights to ChemoCentryx drug

Investigational IBD treatment vercirnon disappoints in phase III

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links